Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

An inverse correlation between the morbidity of rheumatoid arthritis and daily intake of β-cryptoxanthin has been epidemiologically shown. In this study, we investigated the effects of β-cryptoxanthin on the metabolism of cartilage extracellular matrix in vivo and in vitro. Oral administration of β-cryptoxanthin (0.1-1 mg/kg) to antigen-induced arthritic rats suppressed the loss of glycosaminoglycans in articular cartilage, which is accompanied by the interference of aggrecanase-mediated degradation of aggrecan. Inhibition of the interleukin 1α (IL-1α)-induced aggrecan degradation by β-cryptoxanthin was also observed with porcine articular cartilage explants in culture. β-Cryptoxanthin (1-10 μM) dose-dependently down-regulated the IL-1α-induced gene expression of aggrecanase 1 (ADAMTS-4) and aggrecanase 2 (ADAMTS-5) in cultured human chondrocytes. Moreover, β-cryptoxanthin was found to augment the gene expression of aggrecan core protein in chondrocytes. These results provide novel evidence that β-cryptoxanthin exerts anti-arthritic actions and suggest that β-cryptoxanthin may be useful in blocking the progression of rheumatoid arthritis and osteoarthritis.

Type

Journal article

Journal

Biochemical and biophysical research communications

Publication Date

08/2016

Volume

476

Pages

352 - 358

Addresses

Department of Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo, Japan.